APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE 200 MG
NEVIRAPINE : 200 MG ZIDOVUDINE : 300 MG LAMIVUDINE : 150 MG · DIN 02281368 · APOTEX INC
Health Canada status: APPROVED
What is APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE?
APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE 200 MG contains NEVIRAPINE : 200 MG ZIDOVUDINE : 300 MG LAMIVUDINE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02281368, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 30-May-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE used for?
Treatment of HIV-1 infection in settings where more preferred therapies cannot be used. Not evaluated in clinical trials; based on bioavailability studies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02281368 |
|---|---|
| Brand name | APO-ZIDOVUDINE-LAMIVUDINE-NEVIRAPINE |
| Generic / active ingredient | NEVIRAPINE : 200 MG ZIDOVUDINE : 300 MG LAMIVUDINE : 150 MG |
| Manufacturer | APOTEX INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AR05 ZIDOVUDINE, LAMIVUDINE AND NEVIRAPINE |
| AHFS class | 08:18.08.16 ; 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 30-May-2016 |
How is it administered?
Fixed-dose combination. A 14-day lead-in period with nevirapine 200 mg daily must be strictly followed before escalating to twice daily dosing to reduce rash frequency.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refers to a separate section).
How is it supplied?
Not explicitly detailed in the provided text (refers to a separate section).
Contraindications
Hypersensitivity; co-administration with lamivudine, zidovudine, or nevirapine; low neutrophil count (<0.75 x 10^9/L) or hemoglobin (<75 g/L); severe hepatic impairment; St. John’s wort.
Warnings and precautions
Fatal hepatotoxicity and severe skin reactions (SJS/TEN) especially in first 18 weeks. Lactic acidosis. Post-treatment HBV exacerbation. Risk higher in women and higher CD4 counts.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.